Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
The success of adipose stem cells

Cell therapy specialist TiGenix has announced that their product for the treatment of complex perianal fistulas, Cx601, has met the primary endpoi…


Stem cell patch restores vision to the blind

A stem cell patch has successfully restored sight to two blind patients in the UK. The Phase I trial is the first of its kind to use a whole engin…


New drug for intestinal fibrosis

Researchers from Ghent University Hospital have forced a breakthrough in the fight against intestinal fibrosis, a complication that occurs especia…

POPULAR TAGS

Cell therapy for Crohn's disease gets FDA boost to enter US market

Written by DS on in the category news with the tags , , .


TiGenix NV, an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on an improved protocol for its global Phase III trial for the treatment of complex perianal fistulas in Crohn's disease patients. This might accelerate the commercialization in the US.

You might also be interested in 'Faeces transplant as treatment for Crohn's disease'

On August 2015, TiGenix received the FDA endorsement of a Special Protocol Assessment (SPA) for a pivotal Phase III study for Biologics License Application (BLA) in the U.S. Since the granting of the SPA, further confirmatory positive results have been obtained from the European Phase III study of Cx601 (ADMIRE-CD), the largest randomized study performed so far in Crohn's disease patients with complex perianal fistulas. Subsequently, TiGenix submitted a Marketing Authorization Application to the European Medicines Agency in March 2016. Following the publication of this additional data, TiGenix submitted a series of technical improvements to be considered by the FDA regarding the previously endorsed protocol.

Based on the minutes from a meeting with the FDA on January 19, 2017, the Agency has agreed to an improved protocol for the global Phase III trial of Cx601. With these current amendments, the FDA has agreed that the BLA could be filed based on the efficacy and safety follow-up of patients assessed at week 24, instead of week 52. Furthermore, the FDA has agreed to accept fewer patients than originally planned in the study, and has endorsed a broader target population that will ultimately facilitate the recruitment process. With these adjustments, the study will benefit from an expedited recruitment process that should lead to shorter timelines, an earlier filing, and the possibility of an earlier approval in the U.S. As a result of these modifications, the trial design is even more similar to the European ADMIRE-CD than it was before.

"We are pleased to have had the opportunity to meet with the FDA and receive the Agency endorsement for our proposals for this improved protocol," said Dr. Maria Pascual, VP Regulatory Affairs & Corporate Quality of TiGenix. "We continue to be focused and committed to bringing Cx601 to U.S. patients as soon as possible. We believe that this revised protocol will allow us to file for approval one year earlier than we had originally planned," concluded Dr. Pascual.

The global pivotal Phase III trial for the U.S. registration of Cx601 is expected to begin in the first half of 2017. In parallel, TiGenix is exploring further expedited pathways to accelerate the submission and review process for its future BLA.

Read more about TiGenix

RELATED ARTICLES
The success of adipose stem cells

Cell therapy specialist TiGenix has announced that their product for the treatment of complex perianal fistulas, Cx601, has met the primary endpoi…


Stem cell patch restores vision to the blind

A stem cell patch has successfully restored sight to two blind patients in the UK. The Phase I trial is the first of its kind to use a whole engin…


New drug for intestinal fibrosis

Researchers from Ghent University Hospital have forced a breakthrough in the fight against intestinal fibrosis, a complication that occurs especia…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

Biowin Janssen Itera Life Science V-Bio Ventures Flanders.bio Turnstone GSK XpandInnovation KU Leuven UGent

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.